Fulgent Pharma, a subsidiary of Fulgent Genetics, presented data at ASCO 2024 showing promising results for their therapeutic candidate, FID-007, in treating head and neck cancer.
Phase 1 clinical trials evaluated FID-007 in 11 head and neck squamous cell carcinoma patients. Of these, 45% experienced a partial response, and 27% achieved stable disease. Notably, the drug was well-tolerated, with no high-grade neuropathy observed.
FID-007 demonstrated anti-tumor activity in patients who had previously received taxane treatment. The duration of follow-up ranged from 1 to 15 months.
Encouraged by these findings, Fulgent Pharma has initiated a Phase 2 study combining FID-007 and cetuximab in patients with head and neck cancer. The drug’s unique formulation, which encapsulates paclitaxel in a polymer excipient, enhances its pharmacokinetics, distribution, and tolerability. The nanoparticle formulation targets tumors’ leaky vasculature, delivering paclitaxel directly to cancer cells.
Fulgent Pharma’s commitment to advancing cancer therapeutics is evident in its partnerships with leading institutions such as the University of Southern California, Moffitt Cancer Center, and ANP Technologies. The company remains dedicated to developing innovative drug candidates that address the unmet needs of cancer patients.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
